Deshmukh Rashmi, Joshi Vineet, Singh Vivek, Basu Sayan
Shantilal Shanghvi Cornea Institute, LV Prasad Eye Institute, Hyderabad, Telangana, India.
Centre for Ocular Regeneration (CORE), Prof. Brien Holden Eye Research Centre (BHERC), L V Prasad Eye Institute, Hyderabad, Telangana, India.
Indian J Ophthalmol. 2025 Apr 1;73(4):537-542. doi: 10.4103/IJO.IJO_1974_24. Epub 2025 Mar 27.
Corneal blindness affects millions worldwide, with a particularly high burden in developing regions, especially in Asia and Africa. In India, the scarcity of donor corneal tissue and challenges in post-transplant care complicate efforts to address this issue. While enhancing the eye banking network and increasing surgical training remain important, corneal transplantation alone cannot address the problem, particularly for high-risk cases such as trauma, infections, and degenerative diseases, which often have poor long-term outcomes. Advances in regenerative medicine and bioengineering offer promising alternatives. Cell-based therapies, including cultivated limbal epithelial and mesenchymal stem cell treatments, aim to restore corneal function through the modulation of native cell behavior. Additionally, cell-free therapies, such as exosomes, decorin, and extracellular matrix derivatives, provide innovative, donor-independent options to reduce scarring and promote healing. Bioengineered corneas and hydrogel scaffolds further reduce dependence on donor tissue, expanding treatment possibilities and alleviating donor shortages. The successful integration of these therapies into clinical practice requires collaboration between research institutions and industry, along with localized manufacturing to ensure affordability and accessibility. To support these advancements, eye banks may need to evolve into comprehensive cell and tissue facilities, ultimately expanding care options for patients with corneal blindness in resource-limited settings.
角膜盲影响着全球数百万人,在发展中地区负担尤其沉重,特别是在亚洲和非洲。在印度,供体角膜组织稀缺以及移植后护理方面的挑战使解决这一问题的努力变得复杂。虽然加强眼库网络和增加手术培训仍然很重要,但仅靠角膜移植无法解决问题,特别是对于创伤、感染和退行性疾病等高风险病例,这些病例往往长期预后不佳。再生医学和生物工程的进展提供了有前景的替代方案。基于细胞的疗法,包括培养的角膜缘上皮细胞和间充质干细胞治疗,旨在通过调节天然细胞行为来恢复角膜功能。此外,无细胞疗法,如外泌体、核心蛋白聚糖和细胞外基质衍生物,提供了创新的、不依赖供体的选择,以减少瘢痕形成并促进愈合。生物工程角膜和水凝胶支架进一步减少了对供体组织的依赖,扩大了治疗可能性并缓解了供体短缺问题。将这些疗法成功整合到临床实践中需要研究机构和产业界的合作,以及本地化生产以确保可承受性和可及性。为支持这些进展,眼库可能需要发展成为综合性的细胞和组织设施,最终为资源有限环境中的角膜盲患者扩大护理选择。